Vertex Announces FDA Approval of JOURNAVX™ (suzetrigine), a …
2 days ago · Vertex Announces FDA Approval of JOURNAVX™ (suzetrigine), a First-in-Class Treatment for Adults With Moderate-to-Severe Acute Pain
FDA Approves Vertex Pharmaceuticals' Suzetrigine for Acute Pain Management
2 days ago · According to a new announcement, the FDA has approved suzetrigine (Vertex Pharmaceuticals), an oral selective NaV1.8 pain signal inhibitor, to treat patients who experience moderate-to-severe acute pain. Marketed as Journavx, the novel, non-opioid therapy becomes the first new class of medicine to treat acute pain in over 20 years. 1 The new drug application …
FDA approves painkiller designed to eliminate risks of addiction ...
1 day ago · 1 of 3 | U.S. officials have approved a new type of pain drug designed to eliminate the risks of addiction and overdose associated with opioids. The Food and Drug Administration approved the pill from Vertex Pharmaceuticals for acute pain that often occurs after surgery or …
What Is Journavx? First Pain Medication Approved by FDA in
1 day ago · Vertex's medication, named Journavx, is seen as a major development in the ongoing effort to provide effective pain management solutions without the harmful consequences associated with opioid ...
FDA approves new type of nonopioid painkiller for acute pain
1 day ago · The Food and Drug Administration approved a new type of nonopioid painkiller, Journaxv, or suzetrigine, drugmaker Vertex Pharmaceuticals said.
FDA Approves Journavx Drug to Treat Pain Without Addiction Risk
1 day ago · The drug, Journavx by Vertex Pharmaceuticals, blocks pain signals to the brain, making it nonaddictive.
FDA approves new non-opioid pain drug - Nature
2 days ago · In Vertex’s pivotal trials in over 2,000 patients with moderate to severe pain after bunionectomy or abdominoplasty, suzetrigine provided comparable pain relief to an acetaminophen–opioid ...
Vertex Announces Positive Results From the VX-548 Phase 3 …
Jan 30, 2024 · Vertex’s approach is to selectively inhibit NaV1.8 using small molecules with the objective of creating a new class of medicines that have the potential to provide effective relief …
Vertex Pharmaceuticals | R&D Pipeline | Pain
We’re focused on researching and discovering medicines aimed at selectively targeting the underlying cause of pain response, including acute or chronic severe pain caused by a variety …
New Pain Medication Suzetrigine Prevents Pain Signals from …
Aug 20, 2024 · In January 2024 Vertex announced promising results of clinical trials of VX-548, which it is calling suzetrigine, showing that it dampened acute pain levels by about one half on …
- Some results have been removed